Brief: Xbrane Biopharma: Update On Out-Licensing Of Xdivane, Xb003

Xbrane Biopharma AB

21/10/2024 07:35

Oct 21 (Reuters) - Xbrane Biopharma AB  XBRANE.ST :
    * UPDATE ON ONGOING OUT-LICENSING OF XDIVANE (NIVOLUMAB
BIOSIMILAR
CANDIDATE) AND XB003 (CIMZIA BIOSIMILAR CANDIDATE)
    * REACHED AGREEMENT NEGOTIATION STAGE WITH XDIVANETM AND
RECEIVED
FIRST NON-BINDING PROPOSALS ON XB003
    * COMPANY HAS, VIA AGREED PROLONGED PAYMENT PLANS VERSUS.
MAIN
SUPPLIERS, EXTENDED TIMING TO END OF NOV 2024

Source text for Eikon:  ID:nMFN6d24Gm 
Further company coverage:  XBRANE.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))